The Role of Immune Checkpoint Inhibitors in the Treatment of Genitourinary Cancers: An Interprofessional Perspective on Guideline Updates

The landscape of genitourinary cancer therapy is evolving. As treatment options expand and are integrated into treatment regimens, and guidelines are updated to reflect these advances, there is an ongoing need for the members of the care team to engage in continuing education in this area. Additionally, as the pandemic continues, it’s important that clinicians recognize and apply strategies for reducing the risk of COVID-19 infection in vulnerable patients.

-Review key updated guideline recommendations for treatment algorithms for patients with advanced genitourinary cancer
-Distinguish between targeted therapy and immunotherapy, and combination regimens with respect to treatment options in advanced genitourinary cancer
-Describe key components of patient education and communication concerning targeted therapy, immunotherapy, and combination immuno/VEG-F therapy for advanced genitourinary cancer
-Develop strategies for managing treatment-related toxicities including multidisciplinary care of patients receiving targeted and immunotherapy and combination regimens for advanced genitourinary cancer.